Galecto Inc. announced it raised $79.1 Million in an initial filing from an offering of $124 Million

Company

Location

About

Galecto is a clinical-stage biotechnology company developing novel small-molecule therapeutics that target the core biological drivers of fibrosis, inflammation, and cancer. Founded by leading scientists and biotech executives with more than a decade of research into galectin biology and LOXL2 modulation, the company has built deep expertise in pathways central to complex and often devastating diseases. Galecto is backed by prominent investors including Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure, and SEED Capital.